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Abstract
Background: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few
years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now
standard first-line therapy. However, the majority of patients relapse and require further therapy, and so new, effective,
targeted therapies that improve remission rates, reduce relapses, and have fewer side effects, are required. The FLAIR
trial will assess whether ibrutinib plus rituximab (IR) is superior to FCR in terms of progression-free survival (PFS).
Methods/design: FLAIR is a phase III, multicentre, randomised, controlled, open, parallel-group trial in patients with
previously untreated CLL. A total of 754 participants will be randomised on a 1:1 basis to receive standard therapy with
FCR or IR. Participants randomised to FCR will receive a maximum of six 28-day treatment cycles. Participants
randomised to IR will receive six 28-day cycles of rituximab, and ibrutinib taken daily for 6 years until minimal residual
disease (MRD) negativity has been recorded for the same amount of time as it took to become MRD negative, or until
disease progression. The primary endpoint is PFS according to the International Workshop on CLL (IWCLL) criteria.
Secondary endpoints include: overall survival; proportion of participants with undetectable MRD; response to therapy
by IWCLL criteria; safety and toxicity; health-related quality of life (QoL); and cost-effectiveness.
Discussion: The trial aims to provide evidence for the future first-line treatment of CLL patients by assessing whether
IR is superior to FCR in terms of PFS, and whether toxicity rates are favourable.
Trial registration: ISRCTN01844152. Registered on 8 August 2014, EudraCT number 2013-001944-76.
Registered on 26 April 2013.
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Background
Chronic lymphocytic leukaemia (CLL)
Chronic lymphocytic leukaemia (CLL) is the most com-
mon adult leukaemia, affecting 7.0 per 100,000 popula-
tion [1]. The incidence of CLL increases with age and
twice as many men are affected as women. CLL results
from the clonal proliferation of B-cells and is diagnosed
by the pattern of expression of various cell surface anti-
gens on the CLL cells. Patients most commonly present
with lymphocytosis, lymphadenopathy, splenomegaly
and systemic symptoms such as fatigue, weight loss and
malaise. The clinical course of CLL is highly variable
with a median survival from diagnosis in the region of
7 years. Patients with more advanced disease (Binet’s
stages B, C and progressive stage A) have a significantly
worse survival.
Therapy for CLL
Over the last few years there has been substantial im-
provement in the treatment of CLL. First-line therapy
has moved away from monotherapy using chlorambu-
cil to combination immunochemotherapy such as
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fludarabine, cyclophosphamide and rituximab (FCR)
following evidence from large randomised trials [2].
FCR is the standard therapy, shown to improve sur-
vival over comparable treatments in fit and/or young
patients, but only 75% tolerate a full six cycles. In
addition, there is a small risk of developing late myelo-
dysplasia and acute leukaemia, thought to be due to
the FC chemotherapy. The majority of patients relapse
and require further therapy that is more difficult to ad-
minister, and associated with significant morbidity and
potential mortality. Eventually the majority of patients
die from CLL. Hence, more effective, targeted therap-
ies that improve remission rates and reduce relapses,
with fewer side effects, are required.
Ibrutinib
The proliferation of CLL cells in vivo is dependent on
signalling through the B-cell receptor (BCR) which is
expressed at low levels on CLL cells. BCR activation
leads to the transduction of signals through a series of
intracellular molecules resulting in CLL cell prolifera-
tion. This provides a series of potential therapeutic tar-
gets on the BCR signalling pathway. Bruton’s tyrosine
kinase (Btk) is a key component of the BCR pathway to
the extent that individuals born with mutated Btk pro-
duce no B-cells. Ibrutinib [3] is an orally administered,
small molecule selective irreversible inhibitor of Btk cur-
rently under investigation in B-cell malignancies includ-
ing CLL and small lymphocytic lymphoma (SLL). In
vitro, ibrutinib inhibits purified Btk and selected
members of the kinase family with 10-fold specificity
compared with off-target kinases. Ibrutinib has shown
extremely promising results in relapsed, refractory
CLL as well as in a small number of treatment-naïve
patients [4, 5].
Rationale for proposed study
Combination chemotherapy with FCR has been shown
to be an effective treatment in patients with CLL who
are able to tolerate it. However, FCR is associated with
significant short- and long-term toxicity with virtually
all patients relapsing and eventually becoming refrac-
tory to therapy before dying, either as a complication
of the disease or its therapy (usually due to infection).
Clear evidence that CLL-cell proliferation is dependent
on stimulation through the B-cell receptor presents
new potential targets for CLL treatment, particularly
since this pathway is specific to B-cells. Several mole-
cules on the B-cell receptor pathway have been tar-
geted including Syk, PI3K delta and Btk, and all
demonstrate activity. Of these agents it appears that
ibrutinib is the most potent agent with relatively minor
side effects in the early phase II trials, and the combin-
ation of ibrutinib with a monoclonal antibody should
lead to a more rapid achievement of an objective re-
sponse with the potential to stop ibrutinib earlier than
with monotherapy. Therefore, the combination of ibru-
tinib and rituximab is a logical way to improve the
therapy in CLL.
Methods/design
Trial aims and objectives
The trial aims to compare the effect on progression-free
survival (PFS) of ibrutinib plus rituximab (IR) with that
of FCR in young/fit patients with previously untreated
CLL.
The primary objective of the trial is to assess whether
IR is superior to FCR in terms of PFS, as defined by
IWCLL criteria [6]. Secondary objectives include:
 Overall survival (OS)
 The proportion of participants with undetectable
minimal residual disease (MRD), as defined by
IWCLL criteria
 Response to therapy, as defined by IWCLL criteria
 Safety and toxicity
 Health-related quality of life (QoL)
 Cost-effectiveness
Trial design
The trial is a phase III, multicentre, randomised, con-
trolled, open, parallel-group trial in patients with pre-
viously untreated CLL. A total of 754 participants will
be randomised on a 1:1 basis to receive therapy with
either FCR or IR. Participants randomised to FCR will
receive a maximum of six treatment cycles with each
cycle being repeated every 28 days. Participants rando-
mised to receive IR will receive six cycles of rituximab
with each cycle being received every 28 days. Ibrutinib
will be taken daily for 6 years or until MRD negativity
has been recorded over a period of 6 months or until
disease progression, whichever occurs first. Due to the
different treatment modalities it is not possible to
blind patients or clinicians to treatment allocation.
Trial population
The main inclusion criteria are: being between 18 and
75 years old; B-CLL with a characteristic immunophe-
notype (including small lymphocytic lymphoma);
Binet’s stages B, C or progressive stage A; require ther-
apy by IWCLL criteria; able to provide written in-
formed consent; considered fit for treatment with FCR
as determined by the treating clinician; and ≤ 20% p53
deletion determined by fluorescent in situ hybridisa-
tion (FISH) (full inclusion and exclusion criteria listed
in Table 1).
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• At least 18 years old
• Maximum age of 75 years old
• B-CLL with a characteristic immunophenotype,
including small lymphocytic lymphoma
• Binet’s stages B, C, or progressive stage A
• Requiring therapy by the IWCLL criteria in
that participants must have at least one of the following:
○ Evidence of progressive marrow failure as manifested
by the development of, or worsening of, anaemia
and/or thrombocytopenia
○ Massive (i.e. 6 cm below the left costal margin)
or progressive or symptomatic splenomegaly
○ Massive nodes (i.e. 10 cm in longest diameter)
or progressive or symptomatic lymphadenopathy
○ Progressive lymphocytosis with an increase of more than 50%
over a 2-month period or lymphocyte doubling time (LDT) of less
than 6 months as long as the lymphocyte count is over 30 × 109/L
○ A minimum of any one of the following disease-related
symptoms must be present:
▪ Unintentional weight loss more than or equal to 10% within
the previous 6 months
▪ Significant fatigue (i.e. Eastern Cooperative Oncology Group
performance status (PS)
2 or worse; cannot work or unable to perform usual activities)
▪ Fevers of greater than 38.0 °C for 2 or more weeks without other
evidence of infection
▪ Night sweats for more than 1 month without evidence of infection
• Considered fit for treatment with FCR as determined by the
treating clinician
• World Health Organisation (WHO) PS of 0, 1 or 2
• Able to provide written informed consent
• Biochemical values must be within the following limits within 14 days
prior to randomisation and at baseline:
○ Alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN).
Aspartate aminotransferase (AST)≤ 3 × ULN
○ Total bilirubin≤ 1.5 × ULN, unless bilirubin rise is due to
Gilbert’s syndrome or of non-hepatic origin
• Prior therapy for CLL
• History or current evidence of Richter’s transformation
• Major surgery within 4 weeks prior to randomisation
• Active infection
• >20% p53 deletion, determined by FISH
• Past history of anaphylaxis following exposure to rat
or mouse-derived CDR-grafted humanised monoclonal antibodies
• Concomitant warfarin (or equivalent vitamin K inhibitor) or other
orally administered anticoagulant treatment (anyone requiring
anticoagulation treatment for more than 6 months is not eligible
for trial entry. It is acceptable to be treated with LMW-heparin
for < 6 months on the trial but other anticoagulation should be
discussed with the CI)
• Pregnancy, lactation or women of child-bearing potential unwilling
to use medically approved contraception whilst receiving treatment
and for 12 months after treatment with rituximab has finished,
or 30 days after treatment with ibrutinib has finished, whichever
is the latest. Women must agree to not donate eggs (ova, oocytes)
for the purposes of assisted reproduction
• Men whose partners are capable of having children but who are not
willing to use appropriate medically approved contraception whilst
receiving treatment and for 12 months after treatment with rituximab
has finished, or 3 months after treatment with ibrutinib has finished,
whichever is the latest, unless they are surgically sterile
• CNS involvement with CLL
• Symptomatic cardiac failure not controlled by therapy, or unstable a
ngina not adequately controlled by current therapy (in patients with a
significant cardiac history the left ventricular function should be assessed
and patients with severe impairment should be excluded)
• Respiratory impairment (bronchiectasis or moderate COPD)
• Other severe, concurrent diseases or mental disorders that could
interfere with participant’s ability to participate in the study
• Inability to swallow orally administered medication
• Disease significantly affecting gastrointestinal function and/or inhibiting
small intestinal absorption (malabsorption syndrome, resection of the
small bowel, poorly controlled inflammatory bowel disease, etc.)
• Known HIV positive
• Positive serology for hepatitis B (HB) defined as a positive test for HBsAg.
In addition, if negative for HBsAg but HBcAb positive
(regardless of HBsAb status), a HB DNA test will be performed and if
positive the subject will be excluded (anyone who is
HBsAg − ve/HBcAb + ve/HB DNA–ve should be referred to a liver disease
specialist before the start of treatment with rituximab. During treatment,
participants should be monitored and managed to
prevent HBV reactivation)
• Positive serology for hepatitis C (HC) defined as a positive test
for HCAb, in which case reflexively perform a HC RIBA immunoblot
assay on the same sample to confirm the result
• History of prior malignancy, with the exception of the following:
○ Malignancy treated with curative intent and with no evidence of
active disease present for more than 3 years prior to screening
and felt to be at low risk for recurrence by treating physician
○ Adequately treated non-melanomatous skin cancer or lentigo
maligna melanoma without current evidence of disease
○ Adequately treated cervical carcinoma in situ without current
evidence of disease
• Persisting severe pancytopenia (neutrophils < 0.5 × 109/L or
platelets < 50 × 109/L) unless due to direct marrow infiltration by CLL
• Current treatment with prednisolone of > 10 mg/day
• Active haemolysis (patients with haemolysis controlled with
prednisolone at a dose of 10 mg or less per day can be
entered into the trial)
• Patients with a creatinine clearance of less than 30 mL/min
(either measured or derived by the Cockcroft Gault formula
or alternative locally approved formula)
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Sample size
The trial is powered for the primary endpoint of PFS.
The German CLL8 [7] trial showed a median PFS rate
of 4.5 years in the FCR arm. To assess a superiority
hazard ratio of 0.75 (that is, an improvement in me-
dian PFS to 6 years) with an overall 5% level of signifi-
cance and 80% power, assuming a 4-year recruitment
and a 4-year follow-up period, 355 participants are re-
quired per arm (710 participants overall). Accounting
for a 5% dropout rate, which is in line with previous
Leeds Institute of Clinical Trials Research (LICTR)-led
trials in similar populations, 748 participants are
required in order to observe 379 events.
A formal interim analysis on PFS will be carried out
and reported to the Data Monitoring and Ethics Com-
mittee (DMEC) when half the required number of
events have been observed. This is in order to allow any
large differences between the randomisation arms to be
reported early.
The O’Brien and Fleming alpha-spending function
[8] will be used to adjust for multiple testing in order
to conserve the overall type I error, which recom-
mends that the interim results are compared to a p
value of 0.005, and the final results are then com-
pared to a p value of 0.048. In order to account for
the interim analysis, the O’Brien and Fleming method
recommends increasing the maximum required sam-
ple size and number of events by a factor of 1.008.
Therefore, 754 participants will be recruited to the
FLAIR trial in order to observe 382 events (191 for
the interim analysis).
In order to recruit 754 participants over a 4-year
period, the recruitment target is seven patients per
month for the first 6 months whilst centres are
opening to recruitment and 17 patients per month
thereafter.
Recruitment and consent
Participants will be recruited from multiple research
centres from around the UK. Research centres will be
required to have obtained ethical and management
approvals and undertake a site initiation meeting with
LICTR prior to the start of recruitment into the trial.
Potential participants will be identified by the clinical
team at participating centres based on their diagnosis of
CLL, and will be provided with verbal and written details
about the trial. Informed consent will be collected by
principal investigators at the participating hospitals, after
a recommended minimum of 24 h to read and digest the
information provided.
Randomisation
Following consent, registration and confirmation of eligi-
bility (Table 1), participants will be randomised into the
trial by an authorised member of staff at the trial
research site. Randomisation will be performed centrally
using LICTR automated 24-h telephone randomisation
system.
Participants will be randomised on a 1:1 basis to re-
ceive either FCR or IR and will be allocated a trial num-
ber. A computer-generated minimisation programme
that incorporates a random element will be used to en-
sure that trial arms are well-balanced for the following
participant characteristics: Binet’s stage (B, C or progres-
sive stage A), age (≤65 years, > 65 years), gender (male,
female), and randomising centre.
Data collection and data monitoring
Data will be collected on paper Case Report Forms and
entered into a validated trial database by LICTR. A valid-
ation check programme will be incorporated into the
trial database to verify the data, and discrepancy reports
will be generated for resolution by the investigator. Pri-
ority validations will be incorporated into the validation
programme to ensure that any discrepancies related to
participant rights, or safety, are expedited to sites for
resolution. Data will be monitored for quality and com-
pleteness by LICTR. Missing data will be chased until
received, confirmed as not available or the trial is at ana-
lysis. LICTR/the sponsor will reserve the right to inter-
mittently conduct source data verification exercises on a
sample of participants, which will be carried out by staff
from LICTR/the sponsor. Source data verification will
involve direct access to participant notes at the partici-
pating hospital sites and the central collection of copies
of Consent Forms and other relevant investigation
Table 1 Inclusion and exclusion criteria (Continued)
• History of stroke or intracranial haemorrhage within 6 months
prior to enrolment
• Requirement for treatment with a strong CYP3A4/5
inhibitoror inducer
• Cardiac event (e.g. recent myocardial infarction, coronary artery stent)
requiring dual antiplatelet treatment
CDR complementarity-determining regions, CI chief investigator, CLL chronic lymphocytic leukaemia, CNS central nervous system, COPD chronic obstructive
pulmonary disease, DNA deoxyribonucleic acid, RIBA Recombinant Immunoblot Assay, FISH fluorescent in situ hybridisation, IWCLL International Workshop on CLL,
LMW low molecular weight
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reports. Data will be held on a secure server at the Uni-
versity of Leeds and paper Case Report Forms stored in
a locked unit, both will be accessible only to authorised
trial staff.
QoL and participant-completed health economic data
will be collected for patients who have given consent,
and will be completed by the participant.
Baseline assessments
Baseline assessments to be performed within 4 weeks
of the start of treatment include: complete medical his-
tory, complete physical examination, WHO perform-
ance status, local haematology and biochemistry,
serology for hepatitis B and C, and presence and level
of P53 deletion (within 12 months prior to
randomisation).
Participants will also undergo a chest X-ray if re-
quired, a computed tomography (CT) scan performed
within 8 weeks prior to start of treatment and an elec-
trocardiogram (ECG). Assessment of disease and a
pregnancy test (if the participant is a woman of child-
bearing potential) must also be performed within
2 weeks prior to start of treatment. Blood and bone
marrow samples will be required and sent to the
Haematological Malignancy Diagnostic Service
(HMDS) for flow cytometry (bone marrow samples are
only required if participants have a lymphocyte count
of below 10 × 109/L). For those who have given con-
sent; blood, bone marrow and saliva samples will be
sent to the UK CLL Trials Biobank (see ‘Substudies’
section).
For those who have given consent to QoL question-
naires and health economic assessments, baseline assess-
ments must be completed prior to the participant
becoming aware of their randomisation allocation.
Intervention
Following randomisation to receive FCR or IR; those
participants who receive FCR will receive 24/mg/m2/day
of fludarabine and 150 mg/m2/day of cyclophosphamide
orally on days 1 to 5, in addition to 375 mg/m2 on day 1
of cycle 1 and 500 mg/m2 on day 1 of cycles 2 to 6 of
intravenous rituximab. Cycles of FCR are repeated every
28 days for a total of six cycles.
Participants randomised to IR will receive 375 mg/m2
on day 1 of cycle 1 and 500 mg/m2 on day 1 of cycles 2
to 6 of intravenous rituximab, and 420 mg of orally
administered ibrutinib starting a day prior to the first
dose of rituximab, on day 0 of cycle 1. Cycles of rituxi-
mab are repeated every 28 days for a total of six cycles,
and ibrutinib will be given daily for up to 6 years, until
disease progression, or unacceptable toxicity. The
duration of ibrutinib therapy in responding patients will
be defined by the eradication of MRD. For participants
receiving ibrutinib, MRD will be assessed every 6 months
in the peripheral blood, and if MRD negative, repeated
after 3 months. If the repeat peripheral blood is MRD
negative then after a further 3 months the peripheral
blood and bone marrow will be assessed for MRD. If
both are MRD negative then the patient will receive
the same amount of treatment again as it took for
them to become MRD negative, then they will stop
taking ibrutinib. Participants would then restart ibruti-
nib if they become MRD positive, MRD positivity con-
firmed over 6 months, if MRD positivity is confirmed
within 6 years post randomisation.
Participants will be assessed for their suitability for
treatment within 1 week prior to day 1 of each cycle of
FCR or R (for participants randomised to IR), and 3
monthly for the duration of treatment for participants
randomised to IR, according to standard clinical prac-
tice. For participants randomised to FCR, participants
should be questioned regarding nausea and vomiting
or diarrhoea occurring with the prior cycle of therapy
and if this is present then the fludarabine and cyclophos-
phamide should be given via the intravenous route from
the next cycle onwards due to concerns over drug absorp-
tion. Intravenously administered fludarabine (25 mg/m2/
day on days 1 to 3) and cyclophosphamide (250 mg/m2/
day on days 1 to 3) regimens are recommended if the or-
ally administered regimen is not tolerated. Patients receiv-
ing FCR will receive prophylaxis against Pneumocystis
jirovecii pneumonia (co-trimoxazole or equivalent) and
against herpes virus reactivation (acyclovir). G-CSF (as per
standard dosing) for days 7 to 13 is recommended for all
subsequent cycles of rituximab for participants who have
had to have a previous dose delay due to neutropenia.
Participants can be withdrawn from treatment at the
discretion of the treating clinician, and participants are
free to withdraw consent from treatment or further
follow-up at any time during the trial, without giving a
reason, and without future treatment and care being
affected in any way.
Follow-up assessments
Participants will be followed up as described in the
trial flow diagram (Fig. 1). Participants will be followed
up at 6 monthly intervals from 12 months post ran-
domisation until 7 years post randomisation, with-
drawal, disease progression requiring treatment, or
death, whichever is earliest. Following 6-monthly
follow-up, participants will be followed up annually
until death or withdrawal, whichever is earliest.
Participants will be evaluated for response to treat-
ment and assessment of MRD via bone marrow aspir-
ate, according to the IWCLL response criteria,
3 months after the end of FCR or R (for participants
randomised to IR) and again at the end of ibrutinib for
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participants randomised to IR. MRD will be assessed
throughout the trial according to Fig. 2. A populated
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) figure is also provided in Fig. 3.F3
QoL and health economics questionnaires will be
completed at the end of FCR or R, and then 6 monthly
from 12 months post randomisation for 7 years or until
disease progression, whichever is earliest.
Safety and toxicity data will be assessed continuously
throughout the duration of the trial, as graded by the
Common Terminology Criteria for Adverse Events
(CTCAE) (v4.03) [9]. Events will be categorised as:
suspected unexpected serious adverse reactions (SUSARs);
serious adverse reactions SARs); serious adverse events
(SAEs); adverse events of special interest (AEoSIs); and
adverse events (AEs). AEoSIs are defined as: a major
haemorrhage (resulting in: intraocular bleeding causing
loss of vision; the need for a transfusion of two or more
units of red cells or an equivalent amount of whole blood;
hospitalisation; or the prolongation of hospitalisation); or
an intracranial haemorrhage. Participants experiencing
SAEs and AEs will be assessed from randomisation until
30 days after their last dose of trial treatment. Participants
experiencing SARs, SUSARs and treatment-related deaths
will be assessed from randomisation throughout the dur-
ation of the trial.
Statistical methods and analysis
Statistical analysis is the responsibility of LICTR
statisticians, and a final statistical analysis plan will be
written and signed off before any analysis takes place.
Health economic analyses will be carried out by a des-
ignated health economist at the University of Leeds,
and a separate analysis plan will be written and signed
off before any analysis takes place.
All analyses will be conducted on the intention-to-
treat (ITT) population, where participants will be
included according to the treatment that they were
Fig. 1 Trial flow diagram
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randomised to. A per-protocol (PP) analysis, where
participants will be included according to the treat-
ment they received, will be considered for the primary
endpoint if there are a considerable number of proto-
col violators. The safety population will consist of all
participants who receive at least one dose of treatment,
where participants will be included according to the
treatment that they received.
Primary endpoint analysis
The primary endpoint of PFS will be assessed once 382
events have been observed overall (i.e. 382 participants
have progressed/died). A formal interim analysis will be
carried out when half the number of events (191 events)
have been observed overall. Participants not having pro-
gressed or died at the time of the analyses will be censored
at the last date they were known to be alive and
progression-free. The analysis of primacy will use a Cox
proportional hazards model [10] to compare the trial
arms, adjusting for the minimisation factors excluding
centre, to calculate the hazard ratio and associated 95%
confidence intervals (CIs). The p value will be compared
to 0.048 to account for the formal interim analysis. In
addition, median survival estimates and Kaplan-Meier
curves [11] will be produced by trial arm.
Secondary endpoint analyses
Overall survival will be assessed at the same time as
the primary endpoint using a Cox proportional haz-
ards model to compare the trial arms, adjusting for
the minimisation factors excluding centre. Kaplan-
Meier curves, 95% CIs and median survival estimates
will be produced by trial arm and overall.
The proportion of participants with undetectable
MRD (i.e. MRD negative) will be summarised by trial
arm and overall at each time point that MRD is assessed.
A binary logistic regression model will be used to com-
pare trial arms in terms of the proportion of participants
who become MRD negative at any stage during the trial,
adjusting for the minimisation factors excluding centre.
Time to participants achieving MRD negativity will also
be assessed in the IR arm alone.
Fig. 2 Minimal residual disease (MRD) sampling
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Binary logistic regression models will be used to com-
pare trial arms in terms of the proportion of participants
who achieve a Complete Response (CR or CRi) and who
achieve an Overall Response (at least a PR) at any stage
during the trial, adjusting for the minimisation factors
excluding centre.
Occurrence and frequency of SUSARs, SARs, SAEs,
AEoSIs, AEs and treatment-related deaths will sum-
marised by trial arm and overall. In addition, all events
will be summarised by maximum CTCAE grade
reported and seriousness criteria; and all serious events
will be summarised by MedDRA System Organ Class, by
trial arm and overall.
Mean quality of life (QoL) scores and 95% CIs,
adjusted for the baseline score, will be calculated for all
domains of the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30 and CLL-
specific module EORTC QLQ-CLL16 for each trial arm
and at each assessment time point and overall.
Wilcoxon’s rank sum tests will be used to compare the
change in score for the trial arms from baseline to each
time point.
A cost-effectiveness analysis, incorporating the devel-
opment of a decision analytic cost effectiveness Markov/
semi-Markov state model, using quality-adjusted life
years (QALYs) estimated from utility weights and health
state scores, will be carried out using the euroQol five
dimensions (EQ-5D) and 12-item Short Form Health
Survey (SF12) collected at baseline, end of FCR/R and 6
monthly from 12 months post randomisation.
Pre-specified exploratory analyses will be conducted
for subgroups of interest as appropriate, but will be
interpreted with caution and treated as hypothesis-
generating.
Interim reports
An independent DMEC will review the safety and ethics
of the trial whilst participants are receiving trial treat-
ment; reviewing unblinded safety updates at 3-monthly
intervals, and more detailed unblinded reports annually.
A formal interim analysis on the primary endpoint of
PFS will be reviewed by the DMEC when half of the re-
quired number of events have been observed (191 over
FCR and IR combined). A Cox proportional hazards
model will be used to compare trial arms in terms of
PFS, adjusting for the minimisation factors excluding
centre, where the result will be compared to a p value
of 0.005.
The DMEC, in light of the interim data, and of any
advice or evidence they wish to request, will advise the
TSC if there are any concerns or reasons that the trial
should not continue, or if they believe that the trial
results should be shared further.
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Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
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Trial organisation and administration
The trial was developed by the FLAIR Trial Management
Group (TMG), with the support of the UKCLL/NCRI
CLL Clinical Trials Subgroup. The trial is sponsored by
the University of Leeds ((R&D Office, 34 Hyde Terrace,
Leeds, LS2 9LN); sponsor reference: HM13/10747)),
run and co-ordinated by LICTR, and is registered
(ISRCTN01844152, EudraCT Number 2013-001944-76).
The trial will be conducted in accordance with the princi-
ples of Good Clinical Practice (GCP) in clinical trials, as
applicable under UK regulations, the NHS Research
Governance Framework and through adherence to LICTR
standard operating procedures (SOPs). LICTR and the
sponsor have systems in place to ensure that serious
breaches of GCP of the trial protocol are identified and re-
ported. A sample of data will be assessed by on-site source
data verification by LICTR and this is not independent
from the sponsor. The University of Leeds will be liable
for negligent harm caused by the design of the trial. No
additional compensation for clinical negligence will be
provided for trial participants over that which is available
to NHS patients. Ibrutinib was only provided by the spon-
sor for the duration of protocol treatment and subsequent
treatment will be as per standard care.
A core Internal Project Team (IPT), a TMG, a TSC,
and a DMEC will be established. The independent
DMEC will review the safety and ethics of the trial, as
overseen by the independent TSC. The TSC will monitor
trial progress and the overall direction. The results of
the study will be published in peer-reviewed publications
and will be presented at relevant national and inter-
national conferences. There are no plans to use profes-
sional writers for presenting the outcomes of this trial.
Any protocol changes are disseminated by LICTR to the
relevant parties. A Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) Checklist has
been prepared for this manuscript (Additional file 1).
Protocol amendments
The trial opened to recruitment in August 2014 using
protocol version 1.0 (6 March 2014).
The protocol was amended to version 2 on 4 September
2014 to include the additions of long-term orally adminis-
tered anticoagulant use and cardiac events requiring dual
antiplatelet therapy to the exclusion criteria on safety
grounds. This change was implemented before any partici-
pants were randomised.
The protocol was amended to version 3.0 on 29
September 2016 to modify the MRD stopping criteria
based on updated external MRD data. A criteria for
restarting treatment based on MRD relapse was also added
at this point. Secondary endpoints relating to pattern of
MRD relapse, retreatment and MRD response over time in
participants randomised to IR were also added. These
changes were implemented before any participants had
reached either the original or the amended MRD negative
stopping criteria.
Both amendments were reviewed and approved by the
sponsor, the REC and MHRA.
Substudies
Trial participants will also be invited to take part in the
UK CLL Trials Biobank at the University of Liverpool.
Participants are approached at baseline with a separate
consent form (REC reference 14/NW/1014) and biological
samples are sent to the University of Liverpool.
Discussion
The FLAIR trial has been designed in order to assess the
effectiveness of combination therapy with ibrutinib plus
rituximab in terms of PFS in patients with newly diag-
nosed CLL, compared to the current standard of fludar-
abine, cyclophosphamide and rituximab.
There has been considerable enthusiasm for the trial
amongst both clinicians and patients. Current treatments
for CLL are moving away from standard chemotherapy
regimens given over 6 months, towards longer-term treat-
ment with more targeted small molecules. Treatment with
ibrutinib is attractive to patients due to its oral administra-
tion and apparent low toxicity profile compared with FCR.
In England, ibrutinib is currently only available through
clinical trials in the front-line treatment setting for
patients without the 17p deletion, and thus recruitment
into the trial has been positive and above target.
However, the superiority of ibrutinib over the most
effective chemoimmunotherapy (FCR) has yet to been
demonstrated and the long-term effects of ibrutinib have
yet to be fully determined. This trial will follow up par-
ticipants until death to understand the durability of any
response over FCR.
Novel, small molecules, such as ibrutinib, have a
significant financial cost compared with FCR and so it is
vital to collect health economic data. Ibrutinib is cur-
rently licensed for continuous use until disease progres-
sion or unacceptable toxicity. This trial will evaluate a
disease-based stopping rule using minimal residual
disease where ibrutinib treatment will continue until
disease is no longer detectable, the first time that this
has been looked at in the front-line setting.
Trial status
The FLAIR trial opened to recruitment in August 2014
using protocol version 1.0 (6 March 2014) and is cur-
rently recruiting above target. As of 24 February 2017,
537 participants have been randomised. Recruitment is
due to close in August 2018.
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